Table 1.

The main characteristics of the included studies in the meta-analysis.

					AGAP2-AS1 expression
Study	Region	Tumor type	Sample size	TNM stage	High	Low	Cutoff value	Detection method	Outcome measure	NOS
Hui et al 2019[11]	China	PC	46	I–IV	23	23	Median	qRT-PCR	OS	6
Liu et al 2019[15]	China	HCC	137	I–IV	69	68	Median	qRT-PCR	OS, DFS	7
Tian et al 2018[16]	China	GBM	40	NA	20	20	Median	qRT-PCR	OS	7
Qi et al 2017[12]	China	GC	50	I–IV	25	25	Median	qRT-PCR	OS, PFS	8
Li et al 2016[17]	China	NSCLC	80	NA	40	40	Median	qRT-PCR	OS, DFS	6
Hong et al 2020[18]	China	CRC	116	I–IV	58	58	Median	qRT-PCR	OS, DFS	7
Fan et al 2017[9]	China	NSCLC	198	I–IV	99	99	Median	qRT-PCR	OS	8
Tingting et al 2020[19]	China	EOC	80	NA	40	40	Median	qRT-PCR	NA	8
Shao et al 2020[20]	China	PTC	110	I–IV	55	55	Median	qRT-PCR	NA	8
Zheng et al 2019[21]	China	Glioma	91	I–IV	49	42	Median	qRT-PCR	OS	7

AGAP2-AS1 = ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 antisense 1, CRC = colorectal cancer, DFS = disease-free survival, EOC = epithelial ovarian cancer, GBM = glioblastoma, GC = gastric cancer, HCC = hepatocellular carcinoma, NA = not available, NOS = Newcastle–Ottawa quality assessment scale, NSCLC = nonsmall cell lung cancer, OS = overall survival, PC = pancreatic cancer, PFS = progression-free survival, PTC = papillary thyroid cancer.